How does the senescence-associated secretory phenotype work?

The senescence-associated secretory phenotype (SASP) is the collective term for the secreted output of cells that have entered cellular senescence — a state defined by irreversible cell-cycle arrest accompanied by a characteristic pro-inflammatory secretome. SASP comprises inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes that act on the surrounding tissue microenvironment [2]. It is not a single molecule but a functional class of secreted factors, and it is tracked experimentally through circulating protein biomarkers rather than through a fixed sequence, formula, or molecular weight [5].

The signalling work on SASP centres principally on the NF-κB pathway, with mTOR, JAK/STAT, and cGAS-STING also implicated as modulatory axes [4].

Research Studies

SASP and tumour microenvironment remodelling in cancer models

Cellular senescence influences cancer progression through irreversible cell-cycle arrest, immune surveillance, and paracrine signalling mediated by SASP. SASP factors regulate the tumour microenvironment, and their role is condition-dependent — senescent cells may initially limit growth while their persistence can alter the microenvironment in ways that favour progression [2].

CCT/TRiC and therapy-induced senescence in glioblastoma multiforme

In glioblastoma multiforme (GBM), standard therapies including radiotherapy and temozolomide drive many tumour cells into therapy-induced senescence (TIS), marked by permanent proliferation arrest, high metabolic activity, and SASP. Although senescent cells may initially limit growth, their persistence can fuel recurrence by altering the microenvironment while driving immunosuppression and stem-like traits. GBM is also chaperone-dependent, relying on proteostasis networks for growth, invasion, and treatment resistance, and the eukaryotic chaperonin CCT/TRiC has been examined in this context [3].

Senomorphic agents and multi-target SASP modulation

Unlike senolytics, which aim to eliminate senescent cells, senomorphic agents modulate SASP without clearing the cells, thereby preserving their potential physiological functions. Reviewed mechanisms of senomorphic action include inhibition of NF-κB, mTOR, JAK/STAT, and cGAS-STING signalling, with agents classified into categories including repurposed drugs [4].

Circulating SASP biomarkers in human cohorts

When tracked in circulation, SASP factors associate with age-related clinical traits and diseases, raising the possibility that senescence burden and susceptibility to age-related morbidity can be assessed non-invasively in clinical settings. Human-focused evidence has consolidated circulating biomarkers of senescence and examined their modulation by drug and lifestyle-based senotherapeutic interventions [5].

SS-31 peptide and radiation-induced cardiomyocyte senescence

Exposure to ionizing radiation, such as from radiation therapy or accidental exposure, can have adverse effects on the heart, and radiation injury may include cardiomyocyte senescence. In cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), γ-radiation at doses of 2, 5, and 10 Gy inhibited H9C2 proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining. The mitochondrial-targeted peptide SS-31 (elamipretide) was evaluated in these in vitro systems [6].

Piperlongumine and senescent meniscus cells and chondrocytes in knee osteoarthritis

Cellular senescence in cartilage is a driver of knee osteoarthritis (OA) progression, but its role in the meniscus has been less clear. In OA-induced rats, senescence and SASP marker expression was assessed in meniscus and cartilage. Rat meniscus cells and chondrocytes were rendered senescent with H2O2 and treated with candidate senolytics including piperlongumine (PL), with transcriptomic analysis performed to explore the mechanism [7].

Senolytic-regenerative combination therapy in murine accelerated ageing models

Barriers to radical life extension include the inability to use syngeneic, youthful mesenchymal stem cells (MSCs) and the anti-regenerative effects of SASP factors. A combination approach was tested in which senescent cell burden was reduced using SenoVax™, a dendritic cell-based senolytic immunotherapy, combined with syngeneic pluripotent stem cell-derived MSC. Hepatic injury and accelerated ageing were induced in two established murine models: carbon tetrachloride (CCl₄)-mediated liver injury and doxorubicin-induced systemic senescence [8].

Bone ageing as a multiscale degenerative phenomenon

Bone ageing is not merely a process of bone mass loss but a multi-level, networked degenerative phenomenon spanning molecular, cellular, tissue, and system levels. At the macroscopic level, bone ageing is characterized by declines in bone mass, microstructure, and biomechanical properties [1].

Comparison of senolytic and senomorphic strategies

Additional model systems

Beyond the studies above, senescence has been reported as an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43^Q331K mice [9]; radiation-induced atrial fibrillation has been described as driven by cellular senescence via the GATA4–NF-κB pathway and rescued by D/Q senolytic therapy [10]; intracranial aneurysms have been framed as a manifestation of premature vascular ageing involving cellular senescence, inflammaging, and wall degeneration [11]; and cell senescence has emerged as a hallmark and therapeutic target of chronic intracellular infection, with Mycobacterium abscessus reprogramming alveolar macrophages toward a senescent state [12].

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation. https://europepmc.org/article/PMC/PMC13572547
• [2] A Review of Senescence-Associated Secretory Phenotype-Mediated Remodeling of the Tumor Microenvironment. https://europepmc.org/article/PMC/PMC13572038
• [3] From protection to progression: How CCT/TRiC shapes therapy-induced senescence in glioblastoma multiforme. https://pubmed.ncbi.nlm.nih.gov/42624300/
• [4] Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing. https://pubmed.ncbi.nlm.nih.gov/42498087/
• [5] A compendium of circulating biomarkers of senescence in humans. https://europepmc.org/article/PMC/PMC13408882
• [6] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence. https://europepmc.org/article/PMC/PMC13400571
• [7] Piperlongumine attenuates knee osteoarthritis progression by eliminating senescent meniscus cells and chondrocytes. https://pubmed.ncbi.nlm.nih.gov/42322814/
• [8] Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan. https://europepmc.org/article/PMC/PMC13244891
• [9] Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43^Q331K mice. https://pubmed.ncbi.nlm.nih.gov/42759848/
• [10] Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy. https://pubmed.ncbi.nlm.nih.gov/42743874/
• [11] Intracranial aneurysms as a manifestation of premature vascular aging. https://pubmed.ncbi.nlm.nih.gov/42660465/
• [12] Cell senescence emerges as a hallmark and therapeutic target of chronic intracellular infection. https://pubmed.ncbi.nlm.nih.gov/42749705/